RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.
- PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.
- There are two forms of the disease; wet AMD and dry AMD.
- ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.
- The Company’s novel approach includes the use of high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.